GLP-1 receptor agonists associated with lower respiratory sequelae risk in case report analysisCould diabetes drugs help protect lungs? A new analysis of patient stories suggests a link

This study developed a textual time-series corpus from 136 PubMed Open Access single-patient case reports involving glucagon-like peptide-1 receptor agonists (GLP-1RAs). The primary aim was to evaluate automated large language model (LLM) timeline extraction from these reports. The best-performing LLM (GPT5) achieved high event coverage (0.871) and reliable temporal sequencing (0.843).

Using the extracted data, a time-to-event analysis suggested an association between GLP-1RA use and a lower risk of respiratory sequelae compared to non-users. The reported hazard ratio was 0.259, with a p-value of less than 0.05. Absolute event numbers were not reported. No safety, tolerability, or adverse event data from the case reports were provided in the analysis.

Key limitations stem from the study's design. The analysis is based entirely on single-patient case reports, which are inherently observational and subject to reporting bias. The population size is small, and the 'non-user' comparator group is not well-defined. The primary outcome of the underlying reports was not specified, and follow-up duration was not reported. Funding sources and author conflicts of interest were also not reported.

For clinical practice, this analysis generates a hypothesis of an association but does not establish causality. The finding of a lower risk of respiratory sequelae is preliminary and derived from a limited, retrospective data source. Clinicians should interpret this result with caution and await evidence from controlled, prospective studies before considering any clinical implications.